Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
US11566030B2 · kind B2 · utility
0Cited by
0References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 7, 2022 |
| Grant date | Jan 31, 2023 |
| Priority date | — |
| Expiry date | Feb 7, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P7/06
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I: and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.